Evidence map›Paper›PMID 21378963›Full record

ArticleNature structural & molecular biology2011

Structure of the VP16 transactivator target in the Mediator.

Alexander G Milbradt, Madhura Kulkarni, Tingfang Yi, Koh Takeuchi, Zhen-Yu J Sun, Rafael E Luna, Philipp Selenko, Anders M Näär, Gerhard Wagner

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Elongin functions as a loading factor for Mediator at ATF6α-regulated ER stress response genes.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alexander G MilbradtDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Madhura Kulkarni
Tingfang Yi
Koh Takeuchi
Zhen-Yu J Sun
Rafael E Luna
Philipp Selenko
Anders M Näär
Gerhard Wagner
Harvard University · USNational Institute of Advanced Industrial Science and Technology · JP

Funding

T CELL SPECIFIC TRANSCRIPTION COMPLEXESP01GM047467 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAGNER, GERHARD · 1992 to 2017
$28.6M
OverallP41EB002026 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFIN, ROBERT GUY · 2003 to 2018
$17.9M
Acquisition of a 900 MHz NMR SpectrometerP41GM066360 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFIN, ROBERT GUY · 2002 to 2006
$6.7M
Activator-Targeted Subunits of the ARC/MediatorR01GM071449 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI NAAR, ANDERS M · 2005 to 2010
$1.8M
Transcriptional Activator/Coactivator InteractionsR01CA127990 · NCI · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD · 2007 to 2011
$1.6M
NCI NIH HHS CA127990NCI NIH HHS R01 CA127990NIBIB NIH HHS EB002026NIBIB NIH HHS P41 EB002026NIGMS NIH HHS GM071449NIGMS NIH HHS GM47467NIGMS NIH HHS P01 GM047467NIGMS NIH HHS P41 GM066360NIGMS NIH HHS R01 GM071449
6 · The paper itself

Abstract

The human Mediator coactivator complex interacts with many transcriptional activators and facilitates recruitment of RNA polymerase II to promote target gene transcription. The MED25 subunit is a critical target of the potent herpes simplex 1 viral transcriptional activator VP16. Here we determine the solution structure of the MED25 VP16-binding domain (VBD) and define its binding site for the N-terminal portion of the VP16 transactivation domain (TADn). A hydrophobic furrow, formed by a β-barrel and two α-helices in MED25 VBD, interacts tightly with VP16 TADn. Mutations in this furrow prevent binding of VP16 TAD to MED25 VBD and interfere with the ability of overexpressed MED25 VBD to inhibit VP16-dependent transcriptional activation in vivo. This detailed molecular understanding of transactivation by the benchmark activator VP16 could provide important insights into viral and cellular gene activation mechanisms.

Indexed as

Herpes Simplex Virus Protein Vmw65HumansMediator ComplexMutationNuclear Magnetic Resonance, BiomolecularPoint MutationProtein ConformationHerpes Simplex Virus Protein Vmw65MED25 protein, humanMediator Complex

Identifiers

PMID21378963
PMCPMC3076674
OpenAlexW2067950755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.